Ipamorelin
Ipamorelin Acetate
A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
FDA Status
Not FDA-approved — Category 1 (compounding allowed)
Typical Dose
100–300 mcg before bed (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Clinics Indexed
195 providers have offered Ipamorelin in our tracked directory.
Key Reported Benefits
- ✓Clean GH release
- ✓Improved sleep quality
- ✓Fat reduction
- ✓Joint health
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Regulatory & Safety Context
FDA status: Not FDA-approved — Category 1 (compounding allowed)
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
Related Peptides
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
GHK-Cu
B+A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.